This study looked at the risk of blood clots in patients with rheumatoid arthritis (RA) treated with biologics. It found that there was no significant increase in the risk of blood clots with biologics compared to other RA treatments.

This study investigated the occurrence of fatigue (tiredness) in patients with early rheumatoid arthritis (RA) and identified predictors of fatigue after 24 months. The data showed that patients with early disease remission had a rapid, sustained reduction in fatigue and that low disease activity at diagnosis predicted a higher risk of fatigue at 24 months.

This study looked at the use of peficitinib (Smyraf) for the treatment of rheumatoid arthritis (RA) from the perspective of patients and their doctors. It found that peficitinib improved symptoms of RA and led to increased ability to work and carry out daily activities compared to placebo.

This study investigated the relationships among depression and anxiety, diet, and disease activity or physical function in patients with rheumatoid arthritis (RA). The data showed that there was a relationship between depression and lower fish intake frequency in these patients. 

This study investigated whether switching a first-line targeted therapy (TT) within 6 months of not attaining low disease activity (LDA) enhances the chance of patients with rheumatoid arthritis (RA) achieving their target at the 12-month visit. The data showed an increased chance of achieving a target of remission or LDA at the 12-month visit with a TT switch within 6 months.

This study investigated the relationship between tumor necrosis factor-alpha (TNFα), interleukin (IL)-6, and serum certolizumab pegol (CZP; Cimzia) levels in patients with rheumatoid arthritis (RA) treated with CZP. The authors concluded that CZP was highly effective in patients with low serum TNFα levels at 24 hours after the first dose.

This study analyzed the effect of using biological disease-modifying anti-rheumatic drugs (bDMARDs) on fracture risk in patients with rheumatoid arthritis (RA). The data suggest no evidence that the use of bDMARDs impacts fracture risk in these patients.

This study described the guidelines from the Canadian Rheumatology Association (CRA) on the use of COVID-19 vaccines in patients with autoimmune rheumatic diseases (ARDs). The CRA recommended the use of Canada-approved COVID-19 vaccines for patients with ARDs.

This study reviewed the effectiveness of resistance exercise in patients with rheumatoid arthritis (RA). The data showed that resistance exercise can significantly improve disease activity in these patients.

This study assessed the link between smoking and seropositivity levels of specific autoantibodies in patients with rheumatoid arthritis (RA). The authors concluded that patients with RA who were current smokers had significantly higher seropositivity levels than those that never smoked.